Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01085214 · OUTCOME

Progression Free Survival (PFS)

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma · Source last updated 2015-08-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
From registration to progression or death, assessed up to 2 years

What was measured

Median PFS in months. Progressive Disease (PD): Increase of \>= 25% from baseline. Estimated using the method of Kaplan-Meier.

Analysis population: All participants who received study treatment

Groups in this outcome

AZD6244 (Selumetinib) Treatment

Participants received AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
AZD6244 (Selumetinib) Treatment36

Reported measurements

Source class 1
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
AZD6244 (Selumetinib) Treatment3.52Not reported2.605.92Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2.60
        upper Limit
        5.92
        value
        3.52
denoms
  1. counts
    1. group Id
      OG000
      value
      36
    units
    Participants
description
Median PFS in months. Progressive Disease (PD): Increase of \>= 25% from baseline. Estimated using the method of Kaplan-Meier.
dispersion Type
Full Range
groups
  1. description
    Participants received AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    AZD6244 (Selumetinib) Treatment
param Type
MEDIAN
population Description
All participants who received study treatment
reporting Status
POSTED
time Frame
From registration to progression or death, assessed up to 2 years
title
Progression Free Survival (PFS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice